Rhythm Pharmaceuticals (RYTM) News Today $56.50 -0.30 (-0.53%) (As of 09:48 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Position Reduced by State Street CorpState Street Corp trimmed its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,993,166 shares of the company's stock after selling 10,716 shares duDecember 16 at 3:49 AM | marketbeat.comFmr LLC Grows Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Fmr LLC increased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 79.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,295 shares of the company's stock after purchasing an additional 22,306 shaDecember 15 at 3:21 AM | marketbeat.comBNP Paribas Financial Markets Acquires 10,882 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)BNP Paribas Financial Markets grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 307.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,425 shares of the company's stock after acquiring an additional 10,December 12, 2024 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Raised by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 1.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,416,952 shares of the company's stock after buying an additional 4December 10, 2024 | marketbeat.comNational Bank of Canada FI Sells 62,735 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)National Bank of Canada FI decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 15.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 341,507 shares of the company's stock after selling 62,735 shares during the quarDecember 10, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 4.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 225,373 shares of the company's stock afterDecember 8, 2024 | marketbeat.comRhythm Pharmaceuticals: A Key Year AheadDecember 7, 2024 | seekingalpha.comRhythm Pharmaceuticals price target raised to $75 from $64 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comRhythm Pharma: MHRA Expands Marketing Authorization For IMCIVREE - Quick FactsDecember 4, 2024 | markets.businessinsider.comHighVista Strategies LLC Purchases 23,064 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)HighVista Strategies LLC boosted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 160.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,426 shares of the company's stockDecember 3, 2024 | marketbeat.comRhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years OldDecember 3, 2024 | globenewswire.comIntech Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Intech Investment Management LLC purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,386 shares of the company's stoDecember 1, 2024 | marketbeat.comAlkeon Capital Management LLC Acquires 167,700 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Alkeon Capital Management LLC raised its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 16.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,167,700 shares of the company's stock after acquiring anNovember 29, 2024 | marketbeat.comVictory Capital Management Inc. Acquires 11,137 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Victory Capital Management Inc. grew its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 158.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 18,186 shares of the company's stock after acquiring an additional 11,137 sharesNovember 28, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Purchases 143,800 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Healthcare of Ontario Pension Plan Trust Fund grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 14.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,111,043 shares of theNovember 27, 2024 | marketbeat.comPenserra Capital Management LLC Makes New $1.31 Million Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Penserra Capital Management LLC purchased a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 25,063 shares of the company's stock, valNovember 27, 2024 | marketbeat.comAlgert Global LLC Decreases Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Algert Global LLC lowered its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 48.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 54,171 shares of the company's stock after selling 49,961 shares during the quarter.November 27, 2024 | marketbeat.comLoomis Sayles & Co. L P Invests $33.35 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Loomis Sayles & Co. L P bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 636,628 shares of the company's stock, valued at approximately $33,353,000. Loomis SaylesNovember 26, 2024 | marketbeat.comPositive Outlook for Rhythm Pharmaceuticals Boosted by Promising Clinical Outcomes and Anticipated FDA DecisionNovember 25, 2024 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 AnalystsNovember 25, 2024 | benzinga.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $69.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday.November 25, 2024 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from AnalystsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on theNovember 24, 2024 | marketbeat.comPrincipal Financial Group Inc. Acquires 23,054 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Principal Financial Group Inc. grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 241.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,586 shares of the company's stock afteNovember 23, 2024 | marketbeat.comPrimecap Management Co. CA Has $378.09 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Primecap Management Co. CA lessened its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 1.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,216,911 shares of the company's stock after selling 95,480 shares duNovember 21, 2024 | marketbeat.comRhythm Pharmaceuticals’ Advancements in Setmelanotide Trials Signal Strong Buy RatingNovember 20, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)November 20, 2024 | markets.businessinsider.comRhythm Pharmaceuticals announces five presentations at ESPE 2024November 19, 2024 | markets.businessinsider.comBuy Rating Justified for Rhythm Pharmaceuticals Due to Promising Data and Strategic Study ExpansionNovember 19, 2024 | markets.businessinsider.comRhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with SetmelanotideNovember 18, 2024 | globenewswire.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $882,389.64 in StockNovember 14, 2024 | insidertrades.comRhythm announces publication of setmelanotide Phase 3 results in The LancetNovember 14, 2024 | markets.businessinsider.comRhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & EndocrinologyNovember 13, 2024 | globenewswire.comRhythm Pharmaceuticals Announces New Employment Inducement GrantsNovember 13, 2024 | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year High - Still a Buy?Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High - Here's WhyNovember 11, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for RYTM FY2024 Earnings?Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Rhythm Pharmaceuticals in a report issued on Thursday, November 7th. HC Wainwright analyst R. Selvaraju now anticipates that the company wilNovember 11, 2024 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Pamela J. Cramer Sells 4,688 SharesNovember 9, 2024 | insidertrades.comPamela J. Cramer Sells 4,688 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Pamela J. Cramer sold 4,688 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $65.00, for a total transaction of $304,720.00. Following the sale, the insider now directly owns 13,500 shares of the company's stock, valued at approximately $877,500. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.November 8, 2024 | marketbeat.comRhythm Pharmaceuticals’ Common Stock Faces Risks from Convertible Preferred Stock SupremacyNovember 7, 2024 | markets.businessinsider.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comRhythm Pharmaceuticals price target raised to $80 from $53 at Wells FargoNovember 7, 2024 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $69.00HC Wainwright upped their target price on shares of Rhythm Pharmaceuticals from $64.00 to $69.00 and gave the company a "buy" rating in a research report on Thursday.November 7, 2024 | marketbeat.com8,594 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Creative PlanningCreative Planning bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,594 shares of the company's stock,November 7, 2024 | marketbeat.comRhythm Pharmaceuticals Reports Strong Q3 Revenue GrowthNovember 6, 2024 | markets.businessinsider.comNeedham & Company LLC Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) StockNeedham & Company LLC boosted their price objective on Rhythm Pharmaceuticals from $55.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday.November 6, 2024 | marketbeat.comRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comPositive Clinical Data Reinforces Buy Rating for Rhythm Pharmaceuticals Amid Hypothalamic Obesity Treatment AdvancesNovember 6, 2024 | markets.businessinsider.comRhythm Pharmaceuticals: Strong Financial Performance and Pipeline Progress Justify Buy RatingNovember 6, 2024 | markets.businessinsider.comRhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comRhythm Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 5, 2024 | seekingalpha.comRhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year High - Time to Buy?Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 1-Year High - Should You Buy?November 5, 2024 | marketbeat.com Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼1.700.65▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼37▲RYTM Articles Average Week Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Today Dr. Reddy's Laboratories News Today Sarepta Therapeutics News Today Catalent News Today Vaxcyte News Today Qiagen News Today Intra-Cellular Therapies News Today Roivant Sciences News Today Ascendis Pharma A/S News Today Revolution Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts